Replies to post #27555 on Marker Therapeutics Inc (MRKR)

[ClosetInvestor]

Data is limited and early and could not support the over bought/pumped PPS.

The price got run up here in the weeks leading up to the conference and most sold around $9. This happens with many, many biotechs. They hyped the stock, ran it up, and then sold before news.

[drenos2]

Shorter's are relentless. Never thought I'd get caught again, but here I am. They can compete with good science vs their financial horsepower by picking a company with a need for capital to proceed with future phases. MRKR was made to order with a recently announced shelf offering followed by
PR. Their game plan is to pound the share price down, and they aren't done, to ty to force more selling and if they can, force it low enough to cause the company to increase the number of shares from the shelf offering to generate the funds needed. In a word, that's more dilution and with that, they will continue to pound it down.

These people don't care about cancer victims, cardiac patients, Alzheimer sufferers, etc. They will drive a company out of business if they can. Many of you are probably familiar with a company that had great promise in cancer treatment that closed today at 0.1235, has virtually no money and probably will never recover. Congratulations shortees.

That's what we are up against and good news tomorrow or Monday AM won't deter them.

Hopeful nevertheless.